---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-280741"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:45:24.009199+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharma Q3 net loss $51.1M, NERD trial enrollment complete

## Summary
- Net loss of $51.1M in Q3 2022 vs. $36.7M in Q3 2021; R&D expense $19.0M, G&A $23.5M.
- Cash and equivalents $196.8M at Sep 30, 2022; additional $100M available under term loan.
- Completed enrollment in Phase 3 NERD daily dosing trial (776 patients); topline data expected Q1 2023.
- Secured up to $40M additional non-dilutive financing under revenue interest agreement; total capacity $300M.
- Planned Q1 2023 U.S. launches of VOQUEZNA TRIPLE PAK, DUAL PAK, and if approved, VOQUEZNA for EE.

## SEC filing metadata
- accession: 0001193125-22-280741
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/0001193125-22-280741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/d412146d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-280741
- JSON: https://secwatch.observer/filing/0001193125-22-280741.json
- Plain text: https://secwatch.observer/filing/0001193125-22-280741.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the third quarter of 2022 results: net income Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter.
  - Period: the third quarter of 2022
  - Net income: Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter
  - Result: reported results
  source text: On November 8, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/0001193125-22-280741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.